How Elmiron® works for women
Elmiron (Pentosan Polysulfate Sodium) is a semi-synthetic heparin analog that acts locally on the bladder urothelium to restore the protective GAG layer, reduce inflammation, and break the IC/BPS pain cycle — a condition that predominantly affects women.
Understanding IC/BPS Pathophysiology in Women
Defective Urothelium
In women with IC/BPS, the urothelial glycosaminoglycan (GAG) layer is damaged, allowing urinary solutes to penetrate the bladder wall, triggering inflammation and pain.
Mast Cell Activation
Submucosally, mast cells release histamine and other inflammatory mediators, perpetuating the pain-inflammation cycle and causing detrusor muscle irritability — a pattern seen disproportionately in women presenting with chronic pelvic pain.
Neural Sensitization
Chronic inflammation sensitizes bladder afferent nerves, leading to central sensitization and amplified pain perception — hallmarks of IC/BPS that make early recognition in women essential.
How Elmiron® works for women
GAG Layer Restoration
In women with IC/BPS, the bladder's protective glycosaminoglycan (GAG) layer is often compromised. PPS is a synthetic polysaccharide and close analogue of this layer — it adheres to the urothelium, repairing the barrier that shields the bladder wall from urinary irritants.
Anti-inflammatory Action
Elmiron® inhibits mast cell histamine release and reduces submucosal inflammation, breaking the pain-inflammation cycle central to IC/BPS in women. Cystoscopic studies confirm reduction in mucosal redness, scarring, and hyperaemia.
Sustained Symptom Relief
Clinical benefit is duration-dependent, not dose-dependent. Women who responded showed improvement from 5–10 weeks, with benefit continuing to increase over 1–2 years. 80% of women who restarted therapy after stopping experienced rapid symptom return.
Pharmacokinetics
- Absorption
- Poorly absorbed orally (~3–6%). Local action on urothelium is the primary mechanism, not systemic absorption.
- Distribution
- Distributed primarily to the urothelium and liver. Binds to GAG-deficient areas of the bladder wall where protective repair is needed.
- Metabolism
- Hepatic desulfation and depolymerization. Excreted primarily in urine and feces.
- Elimination
- Half-life approximately 4.8 hours after oral dosing. Urinary excretion ~6% of dose.
- Onset
- First signs of improvement typically at 5–10 weeks. Maximum clinical benefit observed at 3–6 months of continuous therapy, with benefit continuing to increase over 1–2 years in long-term use.
35+ years of randomised controlled evidence in women
42–62% experienced moderate to significant symptom improvement. Response increased with duration — some patients reported benefit beyond 90 months of continuous use.
54.2% of women reported >50% improvement on Global Response Assessment (GRA). Efficacy was higher in those who continued therapy beyond one year, and in patients with positive cystoscopic findings at baseline.
"Unequivocally concluded that oral PPS is efficacious compared to placebo in the treatment of bladder pain, urinary urgency, and frequency of micturition." Benefit was even greater in the cystoscopy-confirmed subgroup.
Statistically significant improvement in subjective and objective parameters vs placebo. 80% of responders who restarted PPS after stopping had rapid return of symptom relief, confirming the drug's mechanism is reversible and reproducible.
~49.6% classified as responders at 300mg/day. Response was related to duration of therapy, not dose. All three doses (300, 600, 900 mg/day) showed significant ICSI score improvement at 32 weeks.
Sources: Taneja R. Current status of oral pentosan polysulphate in bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2020. DOI 10.1007/s00192-020-04517-9. Studies referenced are peer-reviewed publications in indexed urology and urogynecology journals.